Altimmune Files 8-K on Security Holder Vote
Ticker: ALT · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1326190
| Field | Detail |
|---|---|
| Company | Altimmune, Inc. (ALT) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Altimmune is calling a shareholder vote on 9/25/25 - details to follow.
AI Summary
On September 25, 2025, Altimmune, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders. No specific details regarding the nature of the vote or the matters to be voted on were provided in this initial filing.
Why It Matters
This filing signals that Altimmune is seeking shareholder approval for certain corporate actions, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain specific financial or operational risks at this stage.
Key Players & Entities
- Altimmune, Inc. (company) — Registrant
- September 25, 2025 (date) — Date of earliest event reported
FAQ
What specific matters will be presented for a vote by Altimmune's security holders?
The 8-K filing dated September 25, 2025, states that matters are being submitted to a vote of security holders, but it does not specify the nature of these matters.
When was this 8-K filing submitted?
The 8-K filing was filed as of September 25, 2025.
What is Altimmune, Inc.'s principal executive office address?
Altimmune, Inc.'s principal executive offices are located at 910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878.
What is Altimmune's fiscal year end?
Altimmune's fiscal year ends on December 31.
What is the SEC file number for Altimmune, Inc.?
Altimmune, Inc.'s SEC file number is 001-32587.
Filing Stats: 660 words · 3 min read · ~2 pages · Grade level 9.7 · Accepted 2025-09-25 16:07:15
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Mar
Filing Documents
- alt-20250925x8k.htm (8-K) — 79KB
- 0001326190-25-000050.txt ( ) — 191KB
- alt-20250925.xsd (EX-101.SCH) — 3KB
- alt-20250925_lab.xml (EX-101.LAB) — 16KB
- alt-20250925_pre.xml (EX-101.PRE) — 10KB
- alt-20250925x8k_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 25, 2025, Altimmune, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting"). As of August 12, 2025, the record date for the 2025 Annual Meeting, there were 88,257,253 shares of the Company's common stock outstanding and entitled to vote at the 2025 Annual Meeting. A total of 51,688,116 shares of common stock were present or represented by proxy at the 2025 Annual Meeting, representing 58.6% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows: Proposal No. 1 : Election of Directors. The results were as follows: Broker Director For Withhold Non-Votes Jerome Durso, Chairman 20,607,586 1,229,401 29,851,129 Vipin K. Garg, Ph.D. 17,425,330 4,411,657 29,851,129 John M. Gill 18,050,621 3,786,366 29,851,129 Philip L. Hodges 14,680,278 7,156,709 29,851,129 Diane Jorkasky, M.D. 14,778,350 7,058,637 29,851,129 Teri Lawver 16,535,619 5,301,368 29,851,129 Wayne Pisano 18,052,060 3,784,927 29,851,129 Mitchel Sayare, Ph.D. 17,619,208 4,217,779 29,851,129 Klaus O. Schafer, M.D., MPH 14,643,908 7,193,079 29,851,129 Catherine Sohn, Pharm D 14,454,283 7,382,704 29,851,129 Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025. The results were as follows: For Against Abstain 48,959,891 1,355,769 1,372,456 Proposal No. 3 : Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "say-on-pay" proposal). The results were as follows: For Against Abstain Broker Non-Votes 14,885,881 6,683,682 267,424 29,851,129 Proposal No. 4